The National Institute of Allergy and Infectious Diseases (NIAID) awarded Yale University a $642,639 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to develop and optimize antibody-targeted, degradable nanoparticles for the selective delivery of therapeutic small interfering RNAs (siRNAs) and gene-editing mRNAs to graft endothelial cells. The goal is to prevent the surface expression of proteins that exacerbate T cell-mediated rejection in solid organ transplants, thereby reducing early rejection episodes and improving long-term graft survival. The 4-year project, starting on September 1, 2024, will involve evaluating the efficacy and durability of the nanoparticle delivery systems in cultured cells, perfused human vessel segments, and a mouse model of transplantation. The project aims to optimize delivery to human kidney and heart grafts using ex vivo normothermic machine perfusion methods.
Generated 3/4/25, 8:41 AM